Composite Inducer for Rapid Mesenchymal Stem Cell Islet Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing mesenchymal stem cells to differentiate into islet cells are inefficient, require lengthy processes, involve ethical concerns, and have low differentiation efficiency, with exogenous insulin failing to maintain normal blood glucose levels.
Innovation Solution
An inducer comprising GLP-1, parathyroid hormone, paracetamol, rapamycin, icariin, trametinib, and VEGF is used to induce mesenchymal stem cells into islet cells, requiring a single step and no genetic modification, with specific mass concentration ratios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current in vitro induction methods are used to differentiate mesenchymal stem cells into islet cells, then differentiation can be achieved, but the induction process is complicated with long induction time and low differentiation efficiency
Solution Approach 1:
The patent combines multiple inducing factors (GLP-1, parathyroid hormone, paracetamol, rapamycin, icariin, trametinib, EPO, and VEGF) into a single composite inducer formulation. This merging of multiple induction agents into one integrated system simplifies the induction process while achieving high differentiation efficiency within 5 days, resolving the contradiction between complicated procedures and low efficiency on one hand, and effective differentiation on the other.
Solution Approach 2:
The patent optimizes the concentration parameters of each inducing factor in the composite inducer (specific mass concentration ratios of GLP-1, parathyroid hormone, paracetamol, rapamycin, icariin, trametinib, EPO, and VEGF) to achieve maximum differentiation efficiency. By precisely controlling these parameter values, the induction time is reduced to 5 days while maintaining high efficiency, thus resolving the time-loss versus productivity contradiction.
2Adaptability or versatility
If embryonic stem cells are used as a source of islet cells, then islet cell transplantation can be achieved, but ethical controversies and difficulty in obtaining cells arise
Solution Approach 1:
Instead of using embryonic stem cells (which raise ethical concerns), the patent inverts the approach by using adult mesenchymal stem cells as the starting material. This inversion of the cell source selection eliminates ethical controversies while maintaining the ability to differentiate into functional islet cells, thus resolving the contradiction between source availability and ethical harm.
3Reliability
If multiple induction steps are used to differentiate stem cells into islet cells, then differentiation can be achieved, but the process becomes complicated with many steps
Solution Approach 1:
The patent merges multiple induction steps into a single-step composite induction process by formulating all necessary inducing factors (GLP-1, parathyroid hormone, paracetamol, rapamycin, icariin, trametinib, EPO, and VEGF) into one integrated inducer. This single-step approach maintains high differentiation success rate while dramatically simplifying the process complexity, resolving the contradiction between reliability and device complexity.
4Reliability
If exogenous insulin is used to treat diabetes, then blood glucose can be controlled, but it cannot constantly maintain normal blood glucose levels as the human body does
Solution Approach 1:
The patent creates functional islet cells from mesenchymal stem cells that possess the self-service capability to autonomously sense blood glucose levels and secrete insulin in response, mimicking the natural physiological regulation system. These differentiated islet cells self-regulate blood glucose without requiring external administration, thus resolving the contradiction between reliable glucose control and physiological adaptability.
Data Source
Figure 1
AI summary
The present invention belongs to the field of biomedicine, and relates to an inducer for inducing a mesenchymal stem cell to differentiate into an islet cell. An inducer for inducing a mesenchymal stem cell to differentiate into an islet cell consisted of the following components: GLP-1, parathyroid hormone, paracetamol, rapamycin, icariin, trametinib, EPO and VEGF. Each component in a inducer for inducing a mesenchymal stem cell to differentiate into an islet cell of the present invention is safe and non-toxic, requiring fewer steps and short time to induce differentiation, with high induction efficiency.